Quick Answer
Matinas BioPharma Holdings, Inc. reported Cash and Equivalents of $4.00 million for fiscal year 2025.
Matinas BioPharma Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.00M | -45.1% |
| 2024 | $7.28M | +52.2% |
| 2023 | $4.79M | -29.9% |
| 2022 | $6.83M | -67.5% |
| 2021 | $21.03M | +69.2% |
| 2020 | $12.43M | -43.9% |
| 2019 | $22.17M | +78.1% |
| 2018 | $12.45M | +70.4% |
| 2017 | $7.31M | +78.0% |
| 2016 | $4.11M | +27.2% |
| 2015 | $3.23M | +24.6% |
| 2014 | $2.59M | -76.1% |
| 2013 | $10.84M | +2454.5% |
| 2012 | $424.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.43M | -47.2% | -16.7% |
| June 30, 2025 | $6.53M | +54.8% | -5.8% |
| March 31, 2025 | $6.92M | +546.5% | -4.9% |
| December 31, 2024 | $7.28M | +52.2% | -29.2% |
| September 30, 2024 | $10.29M | +60.7% | +144.2% |
| June 30, 2024 | $4.22M | -56.7% | +293.7% |
| March 31, 2024 | $1.07M | -81.3% | -77.6% |
| December 31, 2023 | $4.79M | -29.9% | -25.3% |
- Matinas BioPharma Holdings, Inc. showed a decrease of -45.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Matinas BioPharma Holdings, Inc.’s cash and equivalents has grown by 842.4% (from $424.4 thousand to $4.00 million).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: